Teladoc Inc (NYSE:TDOC) was upgraded by TheStreet from a “d” rating to a “c-” rating in a research note issued on Thursday, April 13th.
TDOC has been the topic of several other research reports. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating on shares of Teladoc in a research note on Tuesday, December 20th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Teladoc in a research note on Tuesday, January 10th. Cowen and Company reiterated an “outperform” rating and issued a $29.00 target price on shares of Teladoc in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Teladoc from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Tuesday, January 3rd. Finally, Cantor Fitzgerald started coverage on shares of Teladoc in a report on Thursday, January 5th. They issued an “overweight” rating and a $25.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $27.46.
Teladoc (NYSE:TDOC) traded up 3.63% on Thursday, hitting $28.55. 905,240 shares of the company’s stock were exchanged. The company’s market cap is $1.55 billion. Teladoc has a 12-month low of $9.51 and a 12-month high of $30.98. The company’s 50-day moving average price is $25.92 and its 200-day moving average price is $20.93.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Monday, May 8th. The health services provider reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. The company had revenue of $42.90 million for the quarter, compared to analysts’ expectations of $42.22 million. Teladoc had a negative net margin of 69.15% and a negative return on equity of 32.68%. The business’s revenue was up 59.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) EPS. Analysts forecast that Teladoc will post ($0.88) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/05/19/teladoc-inc-tdoc-upgraded-at-thestreet-updated-updated-updated.html.
In other Teladoc news, VP Mark Hirschhorn sold 59,100 shares of Teladoc stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $25.46, for a total value of $1,504,686.00. Following the completion of the sale, the vice president now directly owns 180,887 shares in the company, valued at $4,605,383.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael H. King sold 5,000 shares of Teladoc stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $25.75, for a total transaction of $128,750.00. Following the completion of the sale, the insider now owns 61,459 shares of the company’s stock, valued at $1,582,569.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 79,100 shares of company stock valued at $1,980,086. 5.94% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of TDOC. Great West Life Assurance Co. Can acquired a new stake in Teladoc during the first quarter worth about $105,000. US Bancorp DE boosted its stake in Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock worth $116,000 after buying an additional 433 shares during the period. Legal & General Group Plc boosted its stake in Teladoc by 66.3% in the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares during the period. Boothbay Fund Management LLC acquired a new stake in Teladoc during the fourth quarter worth about $175,000. Finally, First Mercantile Trust Co. acquired a new stake in Teladoc during the first quarter worth about $175,000. Hedge funds and other institutional investors own 46.61% of the company’s stock.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
What are top analysts saying about Teladoc Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teladoc Inc and related companies.